Disease · MONDO_0019402
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ICL670 vs Crossover: serious adverse events | 102 of 296 | 61 of 259 | 555 | NCT00171210 | Trial comparisons |
| Luspatercept + BSC vs Placebo + BSC: deaths from any cause | 4 of 223 | 1 of 109 | 332 | NCT02604433 | Trial comparisons |
| Luspatercept + BSC vs Placebo + BSC: serious adverse events | 53 of 223 | 8 of 109 | 332 | NCT02604433 | Trial comparisons |
| Mitapivat vs Placebo: deaths from any cause | 0 of 171 | 0 of 87 | 258 | NCT04770779 | Trial comparisons |
| Mitapivat vs Placebo: serious adverse events | 19 of 172 | 13 of 85 | 257 | NCT04770779 | Trial comparisons |
| Deferasirox (Between 2 <16 Years) vs Deferasirox (16 Years or Older): serious adverse events | 5 of 162 | 12 of 69 | 231 | NCT00171301 | Trial comparisons |
| Mitapivat vs Placebo: deaths from any cause | 0 of 130 | 0 of 64 | 194 | NCT04770753 | Trial comparisons |
| Mitapivat vs Placebo: serious adverse events | 8 of 129 | 0 of 63 | 192 | NCT04770753 | Trial comparisons |
| Beta-thalassemia vs Rare Anemias: serious adverse events | 36 of 85 | 50 of 99 | 184 | NCT00303329 | Trial comparisons |
| Luspatercept vs Placebo: Number of Participants With Anti-drug Antibody (ADA) Positive Test for Luspatercept | 5 of 96 | 3 of 49 | 145 | NCT03342404 | Trial comparisons |
| Participants With Severe Beta-globin Disorders in Allogeneic Peripheral Blood Stem Cell Transplants vs Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor: deaths from any cause | 6 of 62 | 0 of 68 | 130 | NCT00061568 | Trial comparisons |
| Participants With Severe Beta-globin Disorders in Allogeneic Peripheral Blood Stem Cell Transplants vs Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor: serious adverse events | 44 of 62 | 6 of 68 | 130 | NCT00061568 | Trial comparisons |
| Deferiprone vs Placebo: The Percentage of Patients in Each Treatment Group Who Still Have a Serum Ferritin Level < 1000 Micrograms Per Liter (μg/L) at Month 12 | 21 of 32 | 12 of 32 | 64 | NCT03591575 | Trial comparisons |
| Deferiprone vs Placebo: deaths from any cause | 0 of 32 | 0 of 32 | 64 | NCT03591575 | Trial comparisons |
| Deferiprone vs Placebo: serious adverse events | 5 of 32 | 2 of 32 | 64 | NCT03591575 | Trial comparisons |
Female Participants With SCD or Beta-thalassemia Receiving Stem Cell Transplant With Male Donor vs Participants With Pre-existing Antibodies and SCD or Beta-thalassemia Receiving Stem Cell Transplant: Number of Participants That Experienced Transplant-related Mortality | 0 of 11 | 0 of 18 | 29 | NCT02105766 | Trial comparisons |
Female Participants With SCD or Beta-thalassemia Receiving Stem Cell Transplant With Male Donor vs Participants With Pre-existing Antibodies and SCD or Beta-thalassemia Receiving Stem Cell Transplant: Percentage of Participant Overall Survival Following Stem Cell Transplant | 10 of 11 | 17 of 18 | 29 | NCT02105766 | Trial comparisons |
Female Participants With SCD or Beta-thalassemia Receiving Stem Cell Transplant With Male Donor vs Participants With Pre-existing Antibodies and SCD or Beta-thalassemia Receiving Stem Cell Transplant: Percentage of Participant With Disease-free Survival Following Stem Cell Transplant | 9 of 11 | 16 of 18 | 29 | NCT02105766 | Trial comparisons |
Female Participants With SCD or Beta-thalassemia Receiving Stem Cell Transplant With Male Donor vs Participants With Pre-existing Antibodies and SCD or Beta-thalassemia Receiving Stem Cell Transplant: Number of Participants That Experienced Regimen Failure | 2 of 11 | 2 of 18 | 29 | NCT02105766 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019402/comparisons